MPO Staff02.25.22
Establishment Labs Holdings Inc. has welcomed a new board member to its leadership ranks.
Marketing executive Leslie Gillin joins the governing body, bringing three decades of experience in senior marketing, product management, and business development to her board position. She is currently chief growth officer of Pagaya, a financial technology company leveraging sophisticated AI-driven credit and analysis technology to enable the credit industry to deliver their customers a positive experience while simultaneously enhancing the broader credit ecosystem.
“I couldn’t be more excited to join the board of Establishment Labs,” said Gillin. “Having highly differentiated products that deliver a much better patient experience in an industry that has been commoditized affords us opportunities to market in ways that have not been previously possible. Our minimally invasive technologies are also a wholly unique opportunity that will allow us to increase the market significantly and to improve the health and lives of women around the world. Direct to consumer strategies and financing programs are going to be essential to unlocking the potential of these new technologies.”
Prior to Pagaya, Gillin served as chief marketing officer of JPMorgan Chase, where her responsibilities included leading firmwide marketing strategy for brand media, advertising, digital marketing, sponsorships and customer research and insights. Prior to chief marketing officer, Gillin was president of the Chase Co-Brand Cards Portfolio, where she grew the portfolio to the largest of its kind in the world. Before her JPMorgan Chase tenure, Gillin was the chief marketing officer of Citibank’s Global Consumer Bank, accountable for driving business growth across 18 countries.
Gillin has also held executive roles at Citigroup, Bank of America, and MBNA. She was named a Top 25 CMO to Watch by Business Insider in 2020.
“We are very pleased to welcome Leslie to the board of Establishment Labs,” said Juan José Chacón-Quirós, founder and CEO of Establishment Labs. “She is accomplished in consumer marketing and finance, and her experience and insights will be invaluable as we continue to transform our industry by engaging directly with patients and by advancing new business and payment models.”
Establishment Labs Holdings Inc. is focused om breast health, principally breast aesthetics and reconstruction. Establishment Labs offers a portfolio of advanced silicone gel-filled breast implants, branded as Motiva Implants. Since commercial launch in 2010, more than 1.8 million Motiva Implants have been delivered to plastic surgeons in over 80 countries. The company also offers or has under development a number of related products and technologies, including the Motiva Flora tissue expander and Motiva MIA, the company’s minimally invasive breast enhancement procedure. In 2018, Establishment Labs received an investigational device exemption (IDE) from the FDA for the Motiva Implant and began a clinical trial to support regulatory approval in the United States. Motiva Implants are manufactured at the company’s two facilities in Costa Rica, which are compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program.
Marketing executive Leslie Gillin joins the governing body, bringing three decades of experience in senior marketing, product management, and business development to her board position. She is currently chief growth officer of Pagaya, a financial technology company leveraging sophisticated AI-driven credit and analysis technology to enable the credit industry to deliver their customers a positive experience while simultaneously enhancing the broader credit ecosystem.
“I couldn’t be more excited to join the board of Establishment Labs,” said Gillin. “Having highly differentiated products that deliver a much better patient experience in an industry that has been commoditized affords us opportunities to market in ways that have not been previously possible. Our minimally invasive technologies are also a wholly unique opportunity that will allow us to increase the market significantly and to improve the health and lives of women around the world. Direct to consumer strategies and financing programs are going to be essential to unlocking the potential of these new technologies.”
Prior to Pagaya, Gillin served as chief marketing officer of JPMorgan Chase, where her responsibilities included leading firmwide marketing strategy for brand media, advertising, digital marketing, sponsorships and customer research and insights. Prior to chief marketing officer, Gillin was president of the Chase Co-Brand Cards Portfolio, where she grew the portfolio to the largest of its kind in the world. Before her JPMorgan Chase tenure, Gillin was the chief marketing officer of Citibank’s Global Consumer Bank, accountable for driving business growth across 18 countries.
Gillin has also held executive roles at Citigroup, Bank of America, and MBNA. She was named a Top 25 CMO to Watch by Business Insider in 2020.
“We are very pleased to welcome Leslie to the board of Establishment Labs,” said Juan José Chacón-Quirós, founder and CEO of Establishment Labs. “She is accomplished in consumer marketing and finance, and her experience and insights will be invaluable as we continue to transform our industry by engaging directly with patients and by advancing new business and payment models.”
Establishment Labs Holdings Inc. is focused om breast health, principally breast aesthetics and reconstruction. Establishment Labs offers a portfolio of advanced silicone gel-filled breast implants, branded as Motiva Implants. Since commercial launch in 2010, more than 1.8 million Motiva Implants have been delivered to plastic surgeons in over 80 countries. The company also offers or has under development a number of related products and technologies, including the Motiva Flora tissue expander and Motiva MIA, the company’s minimally invasive breast enhancement procedure. In 2018, Establishment Labs received an investigational device exemption (IDE) from the FDA for the Motiva Implant and began a clinical trial to support regulatory approval in the United States. Motiva Implants are manufactured at the company’s two facilities in Costa Rica, which are compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program.